{"id":339787,"date":"2026-11-04T22:53:23","date_gmt":"2026-11-04T17:23:23","guid":{"rendered":"https:\/\/univest.in\/blogs-2\/aurobindo-pharma-q2-results-fy27-pat-1124-crore\/"},"modified":"2026-11-04T22:53:23","modified_gmt":"2026-11-04T17:23:23","slug":"aurobindo-pharma-q2-results-fy27-pat-1124-crore","status":"publish","type":"post","link":"https:\/\/univest.in\/blogs-2\/aurobindo-pharma-q2-results-fy27-pat-1124-crore\/","title":{"rendered":"Aurobindo Pharma Q2 Results FY27: Revenue Up 23.87% YoY, Net Profit Up 32.51%, Revenue Rs 10,263.29 Cr, PAT Rs 1,123.84 Cr"},"content":{"rendered":"
\n

Quick Answer<\/strong><\/p>\n

Aurobindo Pharma Q2 Results FY27 were declared on 4 November 2026, and the quarterly results show consolidated revenue of Rs 10,263.29 Cr, up 23.87% YoY from Rs 8,285.70 Cr. Net profit rose 32.51% YoY to Rs 1,123.84 Cr from Rs 848.13 Cr. Operating Profit came in at Rs 2,155.75 Cr, up 28.46% from Rs 1,678.10 Cr. The YoY growth appears in all three lines for the July to September 2026 quarter on a consolidated basis.<\/p>\n<\/div>\n

Aurobindo Pharma Ltd<\/a> (AUROPHARMA) Q2 Results FY27 announced on 4 November 2026, covering the company’s financial performance for the July to September 2026 quarter. The results date brought consolidated revenue of Rs 10,263.29 Cr and PAT of Rs 1,123.84 Cr. Aurobindo Pharma Q2 Results FY27 are reported on a consolidated basis, so every figure here comes from the consolidated results.<\/p>\n

This Aurobindo Pharma Q2 Results article offers a results analysis of the financial highlights, business drivers, outlook and risks behind the numbers. It begins with the Financial Highlights table, which sets revenue, Operating Profit and net profit against the same quarter last year.<\/p>\n

Click Here – Get Free Investment Predictions<\/strong><\/a><\/p>\n

\n
\n

Table of Contents<\/p>\nToggle<\/span><\/path><\/svg><\/svg><\/span><\/span><\/span><\/a><\/span><\/div>\n